Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 clinical trials
Also written SYS6043.
Its developmentBy CSPC Pharmaceutical Group and Conjupro Biotherapeutics, step by step5 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SYS6043
- 4
Studies by the year they started
5 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
CSPC Megalith Biopharmaceutical Co.,Ltd. (4) · Conjupro Biotherapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Bevacizumab (2) · Anti-PD-1/IL-15 Fusion Protein JMT108 (1) · Sintilimab (1)
Studies
Open first, then newest update. How each study uses Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube CancersRecruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07708753Written as SYS6043How we know
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07833735Written as SYS6043How we know
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07761286Written as SYS6090 Injection +SYS6043 Injection +Bevacizumab InjectionHow we know
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid TumorsRecruitingPhase 1Conjupro Biotherapeutics, Inc.NCT07424547Written as SYS6043How we know
- Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid TumorsRecruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07415863Written as SYS6043How we know